Solid Biosciences (SLDB)
NASDAQ:SLDB
Top Page
Solid Biosciences
(NASDAQ:SLDB)
Select Model
Select Model
Rating:57Neutral
Price Target:
$8.50
▲(1.31% Upside)
Action:ReiteratedDate:03/20/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and significant cash burn). Offsetting factors include a technically improving trend and meaningful corporate catalysts, particularly the Phase 1/2 Duchenne data and substantial financing that extends runway.
Positive Factors
Encouraging Phase 1/2 SGT-003 data and FDA alignment
Robust early clinical proof-of-concept with biomarker and cardiac signal plus regulatory alignment materially raises the probability of successful pivotal execution. This strengthens the company’s competitive position in DMD gene therapy and reduces regulatory/design uncertainty over the coming 2–6 months.
Negative Factors
No revenue and widening net losses
A prolonged absence of product revenue and materially widening losses reflect an R&D-stage model that depends on successful clinical outcomes and future commercialization. Persistent losses erode equity cushions and increase dependence on external capital, pressuring long-term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Encouraging Phase 1/2 SGT-003 data and FDA alignment
Robust early clinical proof-of-concept with biomarker and cardiac signal plus regulatory alignment materially raises the probability of successful pivotal execution. This strengthens the company’s competitive position in DMD gene therapy and reduces regulatory/design uncertainty over the coming 2–6 months.
Read all positive factors
Solid Biosciences (SLDB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$789.10M
Dividend YieldN/A
Average Volume (3M)1.45M
Price to Earnings (P/E)―
Beta (1Y)1.87
Revenue GrowthN/A
EPS Growth17.88%
CountryUS
Employees100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding98,391,310
10 Day Avg. Volume877,441
30 Day Avg. Volume1,454,890
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-487.07
Enterprise Value/Ebitda-3.56
Forecast
1Y Price Target
$17.86Price Target Upside112.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.72
Revenue Forecast (FY)N/A
Solid Biosciences Business Overview & Revenue Model
Company Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dy...
How the Company Makes Money
Solid Biosciences has historically generated revenue primarily from its contract development/manufacturing and related services business (Solid Biologics), which provides process development, analytical development, and GMP manufacturing services ...
Solid Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 8.09M | 13.62M |
| Gross Profit | -1.64M | -2.46M | -2.58M | 8.09M | 13.62M |
| EBITDA | -177.57M | -121.90M | -93.43M | -96.87M | -69.29M |
| Net Income | -174.32M | -124.70M | -96.02M | -85.98M | -72.19M |
Balance Sheet | |||||
| Total Assets | 232.54M | 188.66M | 164.94M | 260.25M | 232.38M |
| Cash, Cash Equivalents and Short-Term Investments | 187.85M | 148.92M | 123.64M | 213.72M | 207.78M |
| Total Debt | 21.16M | 24.18M | 26.27M | 28.55M | 2.06M |
| Total Liabilities | 52.53M | 51.42M | 38.46M | 48.59M | 24.17M |
| Stockholders Equity | 180.01M | 137.25M | 126.48M | 211.67M | 208.21M |
Cash Flow | |||||
| Free Cash Flow | -157.44M | -100.67M | -95.69M | -100.99M | -79.05M |
| Operating Cash Flow | -156.29M | -100.01M | -94.18M | -97.98M | -77.76M |
| Investing Cash Flow | -58.45M | -16.09M | 9.69M | 59.16M | -91.09M |
| Financing Cash Flow | 194.45M | 122.44M | 3.12M | 74.83M | 134.99M |
Solid Biosciences Technical Analysis
Positive
8.39
Price Trends
6.87
Positive
6.23
Positive
5.95
Positive
Market Momentum
0.35
Negative
63.29
Neutral
88.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLDB, the sentiment is Positive. The current price of 8.39 is above the 20-day moving average (MA) of 7.45, above the 50-day MA of 6.87, and above the 200-day MA of 5.95, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 63.29 is Neutral, neither overbought nor oversold. The STOCH value of 88.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLDB.
Solid Biosciences Risk Analysis
Solid Biosciences disclosed 88 risk factors in its most recent earnings report. Solid Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Solid Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $789.10M | -2.68 | -73.34% | ― | ― | 17.88% | |
54 Neutral | $1.40B | -33.72 | -15.12% | ― | 1112.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $182.88M | -0.64 | -115.95% | ― | ― | 21.61% | |
48 Neutral | $396.55M | -1.84 | -99.00% | ― | 407.86% | 30.35% | |
47 Neutral | $475.15M | -3.14 | 76.03% | ― | 6.35% | 39.57% |
* Healthcare Sector Average
SLDB
Solid Biosciences
8.39
5.68
209.59%
AUTL
Autolus Therapeutics
1.47
0.13
9.70%
KRRO
Korro Bio
13.69
0.85
6.62%
ADCT
ADC Therapeutics
3.81
2.60
214.88%
GLUE
Monte Rosa Therapeutics
17.55
13.14
297.96%
Solid Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Solid Biosciences Adjusts Board Classes in Governance Move
Neutral
Apr 10, 2026
Solid Biosciences Inc. announced changes to its Board of Directors structure, effective April 10, 2026, to achieve an equal balance of membership among its three director classes. Director Ilan Ganot resigned from his Class III seat, the number of...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data
Positive
Mar 12, 2026
On March 11, 2026, Solid Biosciences reported positive interim data from its first-in-human Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 in 40 pediatric patients with Duchenne muscular dystrophy, based on a February 23, 2026 data cutoff. The treatm...
Business Operations and StrategyPrivate Placements and Financing
Solid Biosciences Announces $240 Million Private Placement Financing
Positive
Mar 6, 2026
On March 6, 2026, Solid Biosciences Inc. entered into a securities purchase agreement with institutional accredited investors for a private placement of 14,973,257 common shares at $5.61 and pre-funded warrants for 27,807,482 shares at $5.609, rai...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.